Gyre Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GYRE and other ETFs, options, and stocks.

About GYRE

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). 

CEO
Ping Zhang
CEOPing Zhang
Employees
5
Employees5
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1997
Founded1997
Employees
5
Employees5

GYRE Key Statistics

Market cap
747.55M
Market cap747.55M
Price-Earnings ratio
198.95
Price-Earnings ratio198.95
Dividend yield
Dividend yield
Average volume
47.85K
Average volume47.85K
High today
$7.77
High today$7.77
Low today
$7.50
Low today$7.50
Open price
$7.64
Open price$7.64
Volume
27.90K
Volume27.90K
52 Week high
$14.42
52 Week high$14.42
52 Week low
$6.11
52 Week low$6.11

Stock Snapshot

Gyre Therapeutics(GYRE) stock is priced at $7.76, giving the company a market capitalization of 747.55M. It carries a P/E multiple of 198.95.

On 2025-12-04, Gyre Therapeutics(GYRE) stock traded between a low of $7.50 and a high of $7.77. Shares are currently priced at $7.76, which is +3.5% above the low and -0.1% below the high.

The Gyre Therapeutics(GYRE)'s current trading volume is 27.9K, compared to an average daily volume of 47.85K.

During the past year, Gyre Therapeutics(GYRE) stock moved between $6.11 at its lowest and $14.42 at its peak.

During the past year, Gyre Therapeutics(GYRE) stock moved between $6.11 at its lowest and $14.42 at its peak.

People also own

Based on the portfolios of people who own GYRE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.